ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint - PACE-CME

ARNI treatment in HFpEF shows benefit in secondary outcomes but misses significance in primary endpoint

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Smartphone-based AF screening in the general population
Smartphone-based AF screening in the general population
ESC 2019
Smartphone-based AF screening in the general population
Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
Betablocker use associated with reduced mortality in HFrEF patients >80 years
Betablocker use associated with reduced mortality in HFrEF patients >80 years
ESC 2019
Betablocker use associated with reduced mortality in HFrEF patients >80 years
- Gianluigi Savarese, MD
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
ESC 2019
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
- Prof. Freek Verheugt